The global next generation drug conjugates market was valued at USD 2.43 Billion in 2025. It is expected to grow at a CAGR of 15.20% during the forecast period of 2026-2035 and attain a market value of USD 10.00 Billion by 2035. The market growth is driven by advancements in targeted therapy techniques and increasing investment in precision medicine. Rising adoption of combination therapies and ligand-mediated delivery systems is expected to enhance treatment efficacy. Continuous research in peptide and RNAi conjugates for cancer and rare diseases is also projected to contribute to market growth during the forecast period.
Base Year
Historical Period
Forecast Period
In April 2023, Novartis collaborated with 3B Pharmaceuticals for developing PRRT candidates that aim at FAP receptors. The development of new candidates are expected to fuel market growth.
In August 2022, PeptiDream partnered with RayzeBio to develop a peptide-RI conjugate targeting GPC3 for liver cancer. Such partnerships will likely elevate the market growth in the forecast period.
The robust regulatory support from health authorities like the FDA is likely to elevate the market value in the coming years.
Compound Annual Growth Rate
15.2%
Value in USD Billion
2026-2035
*this image is indicative*
Next-generation drug conjugates utilize a targeting ligand, a linker, and a payload to enable targeted delivery, integrating non-antibody-based ligands such as peptides, amino sugar, lipids, and small molecules. They use si-RNAs, short nucleic acids, antisense oligonucleotides, and radionuclides as payloads. The market growth for next generation drug conjugates is driven by their increasing application in managing various chronic conditions including cancer.
Technological Advancements to Drive the Market Growth
Advancements in bioconjugation techniques, such as targeted conjugation and enhanced linker designs, are fueling the expansion of the market. These advancements improve the stability and effectiveness of antibody-drug conjugates, overcoming past restrictions and driving market growth.
Growing Need for Cancer Treatments to Boost Next Generation Drug Conjugates Market Demand
Innovative cancer treatments drive the growth of the emerging drug conjugates market. Improvements in antibody-drug conjugates technology enable more precise treatment, minimizing unintended side effects. Such novel technologies enhance stability and effectiveness, by concentrating on enhancing profiles and widening treatment possibilities for solid tumors.
The key trends impacting the current market scenario are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type of Next Generation Drug Conjugates
Market Breakup by Targeting Ligand
Market Breakup by Type of Therapy
Market Breakup by Route of Administration
Market Breakup by Indication
Market Breakup by Region
Market Segmentation Based on the Type of Targeting Ligand to Witness Growth
Based on targeting ligands, the market is segmented into amino sugar, small molecule, peptide, ligand, virus-like particles. The amino sugar section, particularly glucosamine and galactosamine, is expected to lead the market share. These ligands enhance drug delivery and enhance treatment effectiveness by targeting specific receptors on cancer cells.
The market report includes regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is projected to be at the forefront of market share because of well-developed research and healthcare infrastructure. The increasing prevalence of cancer, investments, and treatment adoption also impact the market value positively.
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
In March 2023, Pfizer Inc., headquartered in Manhattan, NYC, purchased Seagen in a USD 43 billion deal. Seagen is recognized for developing antibody-drug conjugates (ADCs) for treating cancer, bolstering Pfizer's oncology lineup and ADC expertise. This action establishes Pfizer as a top player in the expanding market, intending to create enhanced cancer treatments and drive higher profits down the line.
British-Swedish pharma giant AstraZeneca demonstrated dedication to improving cancer treatment technology by constructing a new antibody-drug conjugates ADC manufacturing plant in Singapore. This initiative is designed to increase manufacturing productivity and position AstraZeneca as a frontrunner in the next generation drug conjugates market.
F. Hoffmann-La Roche AG, is a sophisticated antibody-drug conjugate designed for precise cancer treatment, transporting chemotherapy directly to HER2-positive cancer cells. Its accomplishments demonstrate the rise of precision medicine and next-generation drug conjugates in healthcare, along with a rising demand for innovative therapies in cancer treatment.
Daiichi Sankyo, Japan's second-largest pharmaceutical company, plans to independently create advanced ADCs to demonstrate their confidence and align with the market's focus on enhancing cancer treatments.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market are Merck & Co., Inc., ImmunoGen, Inc., Gilead Sciences, Inc., Astellas Pharma Inc., Ambrx Inc., and Takeda Pharmaceutical Company.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type of Next Generation Drug Conjugates |
|
| Breakup by Targeting Ligand |
|
| Breakup by Type of Therapy |
|
| Breakup by Route of Administration |
|
| Breakup by Indication |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share